Biologics have been used increasingly in the treatment and supportive care of cancer;
however, their high cost places a significant burden on healthcare systems. The expiration of …

Biologic-based medicines are used to treat a variety of diseases and account for around one-
quarter of the worldwide pharmaceutical market. The use of biologic medications among …

Biosimilars are the biological product clinically identical to a biologic reference standard
regarding their strength, purity, and safety. A large segment of biosimilars has been …

Biosimilars are biologic products that are highly similar, but not identical, to a licensed
reference (or" originator") biologic product. These agents have the potential to provide …

New diagnostic technologies, including molecular profiling, have enabled advances in
treatments of various cancers; this has significantly improved clinical outcomes, including …

As originator biologic medicines lose patent protection, some biopharmaceutical companies
are focusing on developing similar versions of these costly and complex therapies with a …

Biologics play an integral role in the treatment of cancer not only for their therapeutic effects
and ability to improve outcomes, but also as supportive care agents. Biologics are more …

Four medicinal cancer biological blockbusters will end their patent lifespan by 2020. It is
estimated that the total market for cancer biologicals will reach approximately US $68 billion …

Background The purpose of this report was to review issues associated with the introduction
of alternative versions of biosimilars used in the oncology setting. Design Data were …

Objective To summarize and review the clinical data of Food and Drug Administration (FDA)-
approved biosimilars for use in treatment of cancer and the current challenges health care …